Crotaline (Monocrotaline)

目录号: GN10512纯度: >98.00%同义词: 野百合碱; Crotaline
Crotaline 是一种从 Crotalaria spectabilis 植物种子中提取的吡咯里西啶生物碱,可诱导大鼠肺血管综合征。

Crotaline (Monocrotaline)
Cas No.: 315-22-0
规格价格库存数量操作
50mg¥525.00现货
1
100mg¥770.00现货
1
200mg¥1,400.00现货
1
500mg¥3,150.00现货
1
1g¥5,355.00现货
1
10mM (in 1mL DMSO)¥581.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Crotaline is an pyrrolizidine alkaloid extracted from the seeds of the Crotalaria spectabilis plant to induce pulmonary vascular syndrome in rats[1]. crotaline a natural ligand exhibits dose-dependent cytotoxicity with potent antineoplastic activity. The in vitro cytotoxicity of crotaline is proved at IC50 24.966 μg/mL and genotoxicity at 2 X IC50 against HepG2 cells[2].

In the absence of HepaRG hepatocytes, even at significantly high concentration (1200 μM) for 24 h treatment, Crotaline did not affect viability of HSECs, indicating no cytotoxicity. In contrast, after 24 h treatment in the two-layer transwell co-culture model with co-culture of HSECs and HepaRG hepatocytes, significant decrease in HSEC viability in a concentration-dependent manner was observed for Crotaline[8].

Crotaline causes pulmonary vascular syndrome in rats, characterized by proliferative pulmonary vasculitis, pulmonary hypertension (PH), and cor pulmonale[3].Changes in multiple pathways associated with PH development were observed by crotaline injection, including activated glycolysis, increased proliferation markers, disruption of carnitine homeostasis, increased inflammatory and fibrotic biomarkers, and decreased glutathione biosynthesis[5].Using rats (14 days after exposure to crotaline), changes in multiple pathways associated with the development of PH, including activated glycolysis, increased markers of proliferation, disruptions in carnitine homeostasis, increased inflammatory and fibrosis biomarkers, and a reduction in glutathione biosynthesis[4].PAH induced by Crotaline is a progressive disease with persistent inflammation. The inflammation in Crotaline -PAH model includes acute (the first 6 days after Crotaline injection) and chronic stages (after acute inflammation stage). Acute inflammation stage may be the time window of anti-inflammatory treatment in PAH induced by Crotaline [6,7].

References:
[1]: Gomez-Arroyo JG, Farkas L, et,al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9. doi: 10.1152/ajplung.00212.2011. Epub 2011 Sep 30. PMID: 21964406.
[2]: Kusuma SS, Tanneeru K, et,al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma. Anticancer Agents Med Chem. 2014;14(9):1237-48. doi: 10.2174/1871520614666140715085907. PMID: 25028149.
[3]: Wilson DW, Segall HJ, et,al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22(5-6):307-25. doi: 10.3109/10408449209146311. PMID: 1489509.
[4]: Nogueira-Ferreira R, Vitorino R, et,al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21. PMID: 26403584.
[5]: Rafikova O, Meadows ML, et,al. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung. PLoS One. 2016 Mar 3;11(3):e0150480. doi: 10.1371/journal.pone.0150480. PMID: 26937637; PMCID: PMC4777490.
[6]: Tang C, Luo Y, et,al. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats. Biomed Pharmacother. 2021 Jan;133:111081. doi: 10.1016/j.biopha.2020.111081. Epub 2020 Dec 15. PMID: 33378977.
[7]: Nogueira-Ferreira R, Vitorino R, et,al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21. PMID: 26403584.
[8]: Lu Y, Ma J, Lin G. Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage. Food Chem Toxicol. 2019 Jul;129:391-398. doi: 10.1016/j.fct.2019.04.057. Epub 2019 May 2. PMID: 31054999.

Crotaline 是一种从 Crotalaria spectabilis 植物种子中提取的吡咯里西啶生物碱,可诱导大鼠肺血管综合征[1]。 crotaline 是一种天然配体,具有剂量依赖性细胞毒性和强大的抗肿瘤活性。 crotaline 的体外细胞毒性为 IC50 24.966 μg/mL,对 HepG2 细胞的遗传毒性为 2 X IC50[2]

在没有 HepaRG 肝细胞的情况下,即使在显着高浓度 (1200 μM) 下处理 24 小时,Crotaline 也不影响 HSEC 的活力,表明没有细胞毒性。相比之下,在 HSECs 和 HepaRG 肝细胞共培养的双层 transwell 共培养模型中处理 24 h 后,观察到 Crotaline 浓度依赖性显着降低 HSEC 活力[8].

Crotaline 引起大鼠肺血管综合征,以增殖性肺血管炎、肺动脉高压 (PH) 和肺心病为特征[3]。通过 crotaline 注射液观察与 PH 发展相关的多条通路的变化,包括激活的糖酵解、增殖标志物增加、肉碱稳态破坏、炎症和纤维化生物标志物增加以及谷胱甘肽生物合成减少[5]。使用大鼠(暴露于 crotaline 后 14 天),多条通路发生变化PH 的发展相关,包括激活的糖酵解、增殖标志物增加、肉碱稳态破坏、炎症和纤维化生物标志物增加以及谷胱甘肽生物合成减少[4]。Crotaline 诱导的 PAH 是一种具有持续炎症的进行性疾病。 Crotaline-PAH模型中的炎症包括急性(Crotaline注射后的前6天)和慢性阶段(急性炎症阶段后)。急性炎症期可能是百合碱诱导PAH抗炎治疗的时间窗[6,7]

实验参考方法 Experimental Reference Method

Cell experiment [1]:

Cell lines

HepaRG hepatocytes and HSECs

Preparation Method

HSECs were treated with different concentrations of retrorsine, crotaline (monocrotaline) or clivorine dissolved in ECM containing DMSO (0.5% final concentration) or ECM containing 0.5% DMSO as solvent controls in two-layer transwell co-culture model for 24 h.

Reaction Conditions

100-1200uM,24h

Applications

In the absence of HepaRG hepatocytes, even at significantly high concentration (1200 μM) for 24 h treatment, Crotaline did not affect viability of HSECs, indicating no cytotoxicity. In contrast, after 24 h treatment in the two-layer transwell co-culture model with co-culture of HSECs and HepaRG hepatocytes, significant decrease in HSEC viability in a concentration-dependent manner was observed for Crotaline.

Animal experiment [2]:

Animal models

20 male Sprague Dawley rats (SD; 220-270g)

Preparation Method

Control group received vehicle for crotaline. Pre-pulmonary hypertension (PH) group received a single injection of Crotaline to induce and were sacrificed after 14 days.

Dosage form

A single injection crotaline 60 mg/kg for 14 days

Applications

Changes in multiple pathways associated with PH development were observed by crotaline injection, including activated glycolysis, increased proliferation markers, disruption of carnitine homeostasis, increased inflammatory and fibrotic biomarkers, and decreased glutathione biosynthesis.

References:

[1]. Lu Y, Ma J, Lin G. Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage. Food Chem Toxicol. 2019 Jul;129:391-398. doi: 10.1016/j.fct.2019.04.057. Epub 2019 May 2. PMID: 31054999.

[2]. Nogueira-Ferreira R, Vitorino R, et,al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16. doi: 10.1016/j.pupt.2015.09.007. Epub 2015 Sep 21. PMID: 26403584.

产品文档 Product Documents

Purity:>98.00%

化学性质Chemical Properties

CAS 号
315-22-0
同义词
野百合碱; Crotaline
化学名
(3R,4R,5R,8a1R,13aR)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione
SMILES
O=C([C@@](C([H])([H])[H])([H])[C@@]([C@@]1(C([H])([H])[H])O[H])(C([H])([H])[H])O[H])O[C@@]2([H])[C@](C(C([H])([H])OC1=O)=C([H])C3([H])[H])([H])N3C([H])([H])C2([H])[H]
分子式
C16H23NO6
分子量
325.15 g/mol
溶解性
≥ 67.2 mg/mL in DMSO, ≥ 16.45 mg/mL in ETOH with ultrasonic and warming, ≥ 1.66 mg/mL in Water with ultrasonic and warming
保存条件
4°C, away from moisture and light
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol